Suppr超能文献

生长激素治疗的临床适应证。

Clinical Indications for Growth Hormone Therapy.

机构信息

CHOP Division of Pediatric Endocrinology, Abramson Building, Office 804F, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA.

Children's Hospital of Philadelphia, The Hub for Clinical Collaboration, Division of Endocrinology, 7th floor, 3500 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Adv Pediatr. 2022 Aug;69(1):203-217. doi: 10.1016/j.yapd.2022.03.005. Epub 2022 Jun 17.

Abstract

Growth hormone (GH) is an injectable medication originally used to replace the deficiency of the hormone, but has expanded to treating conditions that may reduce growth and adult height even when the body maintains endogenous GH production. In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Willi Syndrome, small for gestational age (SGA) without catch-up growth, idiopathic short stature, Turner syndrome, SHOX gene haploinsufficiency, Noonan Syndrome, and chronic renal insufficiency. We characterize the growth patterns and effects of GH treatment in each of these indications. We also review patterns of growth that warrant referral to a pediatric endocrinologist, as well as safety updates. This review is intended to guide practitioners on the initial evaluation and management of patients with short stature, and the indications for GH therapy.

摘要

生长激素(GH)是一种可注射药物,最初用于替代激素缺乏症,但已扩展到治疗可能导致生长和成人身高降低的病症,即使体内维持内源性 GH 产生也是如此。在美国,儿科 GH 治疗有 8 种经食品和药物管理局(FDA)批准的适应证:生长激素缺乏症、普拉德-威利综合征、小于胎龄儿(SGA)且未追赶生长、特发性身材矮小、特纳综合征、SHox 基因单倍体不足、努南综合征和慢性肾功能不全。我们描述了这些适应证中 GH 治疗的生长模式和效果。我们还回顾了需要转介给儿科内分泌医生的生长模式,以及安全性更新。本综述旨在指导医生对身材矮小患者进行初步评估和管理,以及 GH 治疗的适应证。

相似文献

1
Clinical Indications for Growth Hormone Therapy.
Adv Pediatr. 2022 Aug;69(1):203-217. doi: 10.1016/j.yapd.2022.03.005. Epub 2022 Jun 17.
2
Current indications for growth hormone therapy for children and adolescents.
Endocr Dev. 2010;18:92-108. doi: 10.1159/000316130. Epub 2010 Jun 3.
3
[Use of recombinant Human Growth Hormone (rHGH)].
Rev Med Inst Mex Seguro Soc. 2017 Mar-Apr;55(2):196-213.
4
Management of Short Stature: Use of Growth Hormone in GH-Deficient and non-GH-Deficient Conditions.
Indian J Pediatr. 2021 Dec;88(12):1203-1208. doi: 10.1007/s12098-021-03892-5. Epub 2021 Oct 5.
5
Indications for growth hormone therapy in children.
Arch Dis Child. 2012 Jan;97(1):63-8. doi: 10.1136/adc.2010.186205. Epub 2011 May 3.
8
A review of guidelines for use of growth hormone in pediatric and transition patients.
Pituitary. 2012 Sep;15(3):301-10. doi: 10.1007/s11102-011-0372-6.
9
Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program.
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4730-4742. doi: 10.1210/jc.2019-00775.
10
The multiple indications for growth hormone treatment of pediatric patients.
Pediatr Ann. 2006 Dec;35(12):926-32. doi: 10.3928/0090-4481-20061201-06.

引用本文的文献

2
Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy.
Neurol Genet. 2025 Aug 27;11(5):e200292. doi: 10.1212/NXG.0000000000200292. eCollection 2025 Oct.
4
7
Impact of growth hormone therapy on bone and body composition in prepubertal children with idiopathic short stature.
J Pediatr Endocrinol Metab. 2025 Apr 22;38(6):624-630. doi: 10.1515/jpem-2025-0085. Print 2025 Jun 26.
8
Gut microbiome and short-chain fatty acids associated with the efficacy of growth hormone treatment in children with short stature.
Front Pediatr. 2025 Mar 31;13:1557878. doi: 10.3389/fped.2025.1557878. eCollection 2025.
9
Efficacy and Safety of Growth Hormone (GH) Therapy in Patients with SHOX Gene Variants.
Children (Basel). 2025 Mar 4;12(3):325. doi: 10.3390/children12030325.
10
Identification of Variants in Vietnamese Patients with Combined Pituitary Hormone Deficiency.
Int J Mol Sci. 2025 Mar 7;26(6):2406. doi: 10.3390/ijms26062406.

本文引用的文献

1
Provocative growth hormone testing in children: how did we get here and where do we go now?
J Pediatr Endocrinol Metab. 2021 Apr 12;34(6):679-696. doi: 10.1515/jpem-2021-0045. Print 2021 Jun 25.
2
Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome.
Front Pediatr. 2021 Feb 2;8:600962. doi: 10.3389/fped.2020.600962. eCollection 2020.
3
Focused Revision: ACMG practice resource: Genetic evaluation of short stature.
Genet Med. 2021 May;23(5):813-815. doi: 10.1038/s41436-020-01046-0. Epub 2021 Jan 29.
4
Cardiovascular Disease in Former Pediatric Recipients of Growth Hormone: Another Look at Growth Hormone Safety.
JAMA Pediatr. 2021 Feb 1;175(2):e205232. doi: 10.1001/jamapediatrics.2020.5232.
6
Variants in the 5'UTR reduce SHOX expression and contribute to SHOX haploinsufficiency.
Eur J Hum Genet. 2021 Jan;29(1):110-121. doi: 10.1038/s41431-020-0676-y. Epub 2020 Jul 9.
7
Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.
Minerva Pediatr. 2020 Jun;72(3):206-225. doi: 10.23736/S0026-4946.20.05821-1. Epub 2020 Apr 9.
8
US Growth Hormone Use in the Idiopathic Short Stature Era: Trends in Insurer Payments and Patient Financial Burden.
J Endocr Soc. 2019 Aug 28;3(11):2023-2031. doi: 10.1210/js.2019-00246. eCollection 2019 Nov 1.
10
Turner syndrome: mechanisms and management.
Nat Rev Endocrinol. 2019 Oct;15(10):601-614. doi: 10.1038/s41574-019-0224-4. Epub 2019 Jun 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验